Managing HIV lipoatrophy

Lancet

Volumn 363, Issue 9407, 2004, Pages 412-414

  Moyle, Graeme ^a   Sutinen, Jussi ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; HUMAN GROWTH HORMONE; LEPTIN; METFORMIN; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; TROGLITAZONE; ZIDOVUDINE;

CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG CHOICE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IATROGENIC DISEASE; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER SIZE; MAXIMUM PERMISSIBLE DOSE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NOTE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 1142273454     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15521-9     Document Type: Note

References (23)

1. Brinkman K., Smeitink J.A., Romijn J.A., Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 354:1999;1112-1115.
2. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 351:1998;1881-1883.
3. Fliers E., Sauerwein H.P., Romijn J.A. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet. 362:2003;1758-1760.
4. Martinez E., Arnaiz J.A., Podzamczer D., et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 349:2003;1036-1046.
5. Hadigan C., Corcoran C., Basgoz N., Davis B., Sax P., Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 284:2000;472-477.
6. Engelson E.S., Glesby M.J., Mendez D., et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr. 30:2002;379-391.
7. Arioglu E., Duncan-Morin J., Sebring N. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 133:2000;263-274.
8. Oral E.A., Simha V., Ruiz E. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 346:2002;570-578.
9. Petersen K.F., Oral E.A., Dufour S., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 109:2002;1345-1350.
10. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 50:2001;1378-1388.
11. Wentworth J.M., Burris T.P., Chatterjee V.K. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARγ/RXR heterodimer. J Endocrinol. 164:2000;R7-R10.
12. Gelato M.C., Mynarcik D.C., Quick J.L., et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr. 31:2002;163-170.
13. Calmy A., Hirschel B., Hans D., Karsegard V.L., Meier C.A. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS. 17:2003;770-772.
14. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. A randomized, double-blind, placebo-controlled study of rosiglitazone for patients with HIV lipodystrophy. Antivir Ther 2003; 8: L12 (abstr).
15. Sutinen J., Häkkinen A.M., Westerbacka J., et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther. 8:2003;199-207.
16. Bastard J.P., Caron M., Vidal H., et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 359:2002;1026-1031.
17. Kannisto K., Sutinen J., Korsheninnikova E., et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS. 17:2003;1753-1762.
18. Mayerson A.B., Hundal R.S., Dufour S. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802.
19. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology. 38:2003;1008-1017.
20. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 51:2002;2796-2803.
21. Carr A, Workman C, Smith D, for the MITOX investigators. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 207-215.
22. John M., McKinnon E.J., James I.R., et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 33:2003;29-33.
23. Moyle G.J., Baldwin C., Langroudi B., Mandalia S., Gazzard B.G. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 33:2003;22-28.